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Abstract 
The aim of this research project is to reprogramme human stem cells into hepatocytes 
in a robust and scalable manner for clinical and industrial applications.  Hepatocytes are the 
parenchymal cells that make up the majority of the liver.  The shortage of hepatocytes and 
difficulty in maintaining primary hepatocytes will remain key obstacles that must be overcome 
by researchers before hepatocyte transplantation can be used in clinical trials.  
Stem cells possess the unique ability to differentiate into any cell type in our body.  In 
addition, they possess the ability to self-renew, meaning, they can act as a renewable source of 
hepatocytes.  Thus, the goal is to differentiate human embryonic stem cells (hES) to 
hepatocyes using cytokines and growth factors (GFs).  Cytokines and growth factors were used 
in the past to mimic embryonic liver development, thus, the goal of this project is to advance a 
step further and to mimic adult liver development.  The difficulty in this system is to translate 
adherent stem cell culture to a suspension culture that better suits their optimal culture 
environment. 
In this project, the focus will primarily be on the differentiation of human stem cells to 
hepatocytes.  After rigorous cell culturing and data collection, it has been found that on day 10 
of differentiation, the cells were well under their way of developing as hepatocytes, however 
they did not show target results for each gene expression tested for.  
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Introduction 
In order to understand the background and technical aspect that this particular research 
project will be undertaking, it is important to understand the current status of the field of stem 
cell technology.   
In addition to the clinical aspects of stem cell-derived hepatocytes, these cells can be 
used in the industrial setting for metabolic studies or further toxicity testing to improve drug 
efficacy1.  Hepatocytes are especially attractive candidates for drug toxicity studies because of 
their active metabolic pathways and signalling during drug metabolism2.  The goal of using 
stem cell-derived hepatocytes would be to use them as an alternative source instead of animal 
trials to better estimate acute and chronic toxicity from certain drugs3.  The shortage of human 
livers makes it extremely difficult to use primary hepatocytes for pharmaceutical purposes 
prompting the need for an alternative source4. 
This need to develop hepatocytes on a larger scale is not limited to the research and 
manufacturing of drugs.  Instead, their use may possibly treat chronic liver diseases that impact 
“over 30 million Americans and over 600 million people”5 all over the world.  However, 
“alternative tissue sources such as fetal hepatocytes and hepatic cell lines are unreliable, 
difficult to reproduce, [as they] do not fully recapitulate hepatocyte phenotype and functions”6, 
and therefore, must be replaced by an alternative source. 
                                                          
1 Li, Albert P. Human Hepatocytes: Isolation, Cryopreservation and Applications in Drug 
Development. N.p., 9 Jan. 2007. Web. 20 Sept. 2014. 
2 Ibid. 
3 JV et al. "Hepatocyte Cell Lines: Their Use, Scope and Limitations in Drug Metabolism Studies." 
National Center for Biotechnology Information. US National Library of Medicine National Institutes of 
Health, Apr. 2006. Web. 20 Sept. 2014. 
4 Si-Tayeb et al. "Highly Efficient Generation of Human Hepatocyte–like Cells From Induced 
Pluripotent Stem Cells." Wiley Online Library. American Association for the Study of Liver Diseases, 1 
Oct. 2009. Web. 20 Sept. 2014. 
5 Schwartz et al. Pluripotent Stem Cell-Derived Hepatocyte-like Cells. Biotechnology Advances. 
Elsevier, 16 Jan. 2014. Web. 20 Sept. 2014. 
6 Ibid. 
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Researchers have looked into using “human embryonic stem (hES) cell and induced 
pluripotent stem (iPS) cells”7 as ‘alternative cell sources’ as hES cells provide a renewable cell 
source of functional human hepatocytes8.  The ultimate end goal would be to use these 
differentiated hepatocytes towards more advanced and ambitious research such as hepatocyte 
transplantation and drug toxicity testing. 
Current state of the art cultivation of stem cells involves 3 dimensional culture of stem 
cells and co-culture with non-parenchymal cells (NPCs) in order to mimic the native 
microenvironment9.  These attempts are techniques researchers have used in order to further 
mature stem-cell derived hepatocytes. 
Current differentiation methods result in iPS-derived hepatocyte-like cells or ES-
derived hepatocyte-like cells possessing some functional hepatic activity similar to primary 
hepatocytes.  Stem cell-derived hepatocytes secrete urea, alpha-1-antitrypsin, and albumin10, 
revealing that the combined phenotypic and functional traits exhibited by ES-derived 
hepatocytes resemble a relatively immature hepatic phenotype that more closely resembles that 
of fetal hepatocytes rather than adult hepatocytes11. 
Therefore, “theoretically, for a cell to become a terminally differentiated cell type, it 
must undergo all consecutive steps of development to be able to respond to the surrounding 
differentiation cues”12 in order to mature into a successful adult hepatocyte.  Thus, keeping this 
                                                          
7 Ibid. 
8 Rambhatla et al. "Generation of Hepatocyte-like Cells From Human Embryonic Stem Cells." Cell 
Transplantation. Ingenta Connect, 1 Nov. 2003. Web. 20 Sept. 2014. 
9 Godoy et al. Recent Advances in 2D and 3D in Vitro Systems Using Primary Hepatocytes, Alternative 
Hepatocyte Sources and Non-Parenchymal Liver Cells and Their Use in Investigating Mechanisms of 
Hepatotoxicity, Cell Signaling and ADME. Springerlink, 23 Aug. 2013. Web. 20 Sept. 2014. 
10 Schwartz et al. Pluripotent Stem Cell-Derived Hepatocyte-like Cells. Biotechnology Advances. 
Elsevier, 16 Jan. 2014. Web. 20 Sept. 2014. 
11 Ibid. 
12 Roelandt et al. Human Embryonic and Rat Adult Stem Cells with Primitive Endoderm-Like Phenotype 
Can Be Fated to Definitive Endoderm, and Finally Hepatocyte-like Cells. N.p., 11 Aug. 2010. Web. 20 
Sept. 2014. 
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end result of a mature hepatocyte in mind, this research project will be based upon the 
imitation of the step-by-step process which is followed by the hepatocytes in vivo and will be 
reconstructed in vitro. 
 This research project will then contribute to the already existent researches as it would 
verify the practicality of the aforementioned theoretical process on the development of mature 
hepatocytes through the imitation of the step-by-step biological process occurring in vivo.  
Thus, the objective of this research is to develop a robust process of producing stem cell-
derived hepatocytes.   
Materials and Method 
In this project, various materials were used, and the methods that were used in this 
project have been described below. 
Since human stem cells were used in this project, it was important to grow them in a 
medium to maintain their pluripotent state and inductive of growth.  Therefore, this project 
used basic Fibroblast Growth Factor (FGF) in order to maintain the pluripotency of the stem 
cells as demonstrated by a number of research groups.  Cells were then grown in a high 
glucose DMEM solution to provide the adequate nutrient and metabolites for optimal growth 
and survival of the cells. 
Once the stem cells were confluent and ready for expansion in a feeder environment, 
they were passaged in order to increase the surface area on which the cells could attach, 
thereby increasing the number of hES cells.  Once adequate amount of cells were cultures, the 
process of differentiation was initiated.  It is a 20-day procedure in which stem cell samples on 
Days 0, 6, 10, 14 and 20 are collected for analysis. 
Differentiation was done in 12 well plates (Corning 12 wells 3513) which were then 
coated with 2% Matrigel (BD 356231) and diluted in PBS solution (Gibco 10010).  These 
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wells were then kept for 1 hour in a 21% O2 – 5.8% CO2 - 37°C incubator.  Once the hES were 
transferred from 6 well plates onto the aforementioned 12 well plates, 4 different stage media 
were used in order to initiate the differentiation process13.  
Figure 1.0: Diagram showing the progression of the differentiation procedure for hepatocytes 
 
Once the differentiation procedure was completed, it was important to test whether the 
cells resembled primary hepatocytes in the body.  For this step, it was necessary to carry out 
quantitative reverse transcription polymerase chain reaction (RT-qPCR).  Therefore, a 
commercially available RNeasy mini kit / micro – kit (Quagen 74104 and 74004) was used to 
carry out RNA isolation.  The next step was to synthesise cDNA, for which 1 µg of RNA with 
Superscript III First-Strand synthesis system (Invitrogen 11733-046) was used.  Finally, SYBR 
Green Platinum SYBR green qPCR Supermix-UDG (Invitrogen 11733-046) was used to 
                                                          
13 See Figure 1.0 
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perform real time PCR.  Once the gene levels were measured, the relative expression of every 
gene was calculated with respect to GAPDH expression14.   
Results 
 
Differentiation 
Day 
GAPDH OCT4 SOX2 CXCR4 ALB TAT GSC 
0 22.19 37.39 24.58 36.7 - - - 
10 18.77 - 23.56 30.01 34.71 35.44 36.27 
 
Figure 2.0: Table showing cycle number at which the respective genes were expressed 
 
Differentiation 
Day 
OCT4 SOX2 CXCR4 ALB TAT GSC 
0 3.27 -3.05 14.51 - 9.43 7.24 
10 21.27 6.75 6.95 18.56 17.52 17.16 
 
Figure 3.0: Table showing the performance of each gene with respect to the Gapdh gene (∆CT) 
  
Figure 4.0: Graph showing the gene expression levels in hepatocyte-like cells 
                                                          
14 See Figures 2.0, 3.0 and 4.0 
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Discussion 
The results for PCR after differentiation should show different trends for different 
genes.  For example, genes Oct 4 and Sox2 should have a ∆CT ranging from negative numbers 
to 3 for Day 0 of differentiation, CXCR4 and GSC should have a ∆CT ranging from 4 to 10 for 
Day 10 samples and ALB and TAT (liver markers) should range from 10 to 15 on Day 10 and 
14 of differentiation.  Therefore, a negative number / small positive value of ∆CT means high 
expression of that gene whereas a high positive value of ∆CT means low gene expression.   
Therefore, ideally, Oct 4 and Sox 2 should have a high expression at the beginning of 
differentiation and low differentiation after differentiation of the cells has occurred.  CXCR4 
and GSC should show medium expression around Day 10 of differentiation, and finally the 
liver markers, i.e. ALB and TAT should have low gene expression at the beginning of 
differentiation and a high expression level near the end of differentiation. 
In this project, Oct 4 and Sox 2 show results on Day 0 as expected, CXCR4 and GSC 
show expression very close to the desired expression levels on Day 10 and finally, ALB and 
TAT show a fair amount of expression on Day 10. 
Therefore, we can infer from the above data that the differentiation began without much 
hindrance, which is why the data for Day 0 is as expected.  However, it is quite possible that 
the project ran into a few obstacles which is why the differentiation deviated from the right 
track in the middle of the differentiation, i.e. Day 10.   
A possible explanation for these unexpected results during and near the end of 
differentiation is the utilisation of a not-well differentiated cell culture well.  There could be 
several reasons for why the cells in this particular well were not differentiating properly.  For 
example, the cell media for each stage of differentiation could be flawed, or even before that, 
while the hES cells were attached onto the Mouse Embryonic Fibroblast (MEF) cells, the H9 
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media could have been partially differentiated to begin with.  In addition, assuming all went 
well before the differentiation, it is quite possible that some of the primers failed to work 
properly which is why the data is not cohesive.   
Thus, in order to reduce the possibility of incorrect differentiation at any given stage of 
the project, it is highly recommended to perform PCR on Day 0 of differentiation, as a flawed 
Day 0 PCR result will be indicative of a flawed Day 20 hepatocyte result in the future. 
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